Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status Prescription; Discontinued
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual field defect06.02.07.003; 17.17.01.001--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
White blood cell count decreased13.01.06.0120.005831%
White blood cell count increased13.01.06.0130.002282%Not Available
Osteopenia15.02.03.003; 14.04.04.0040.005831%Not Available
Pneumomediastinum22.09.03.0040.005831%Not Available
Eschar12.01.08.008; 23.03.03.027--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Growth retardation15.03.01.006--
Transaminases increased13.03.01.015--Not Available
Angiopathy24.03.02.007--Not Available
Induration08.01.03.020--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.003042%
Drug intolerance08.06.01.0130.008747%Not Available
Knee deformity15.10.03.0020.002282%Not Available
Renal impairment20.01.03.0100.008747%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.005831%Not Available
Osteonecrosis of jaw15.02.04.010; 24.04.05.0050.008747%
Iron overload14.13.03.002; 12.02.08.0050.001521%
Metaphyseal dysplasia15.11.06.006; 03.11.06.006--Not Available
Liver injury09.01.07.022; 12.01.02.0030.005831%Not Available
Acute kidney injury20.01.03.016--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages